{"ModuleTitle": "Company Description", "CompanyName": "Immunomedics, Inc.", "Symbol": "IMMU", "Address": "300 AMERICAN RD, MORRIS PLAINS, New Jersey, 07950, United States of America", "Phone": "9736058200", "Industry": "Biotechnology: In Vitro & In Vivo Diagnostic Substances", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "On December 14, 2018, the Company's Board of Directors approved a change in the\r\nCompany's fiscal year end from June 30 to December 31. In connection with this\r\nchange, we previously filed a Transition Report on Form 10-K to report the\r\nresults of the six-month transition period from July 1, 2018 to December 31,\r\n2018 (which we sometimes refer to as the \"Transition Period\"). In this Annual\r\nReport, the periods presented are the year ended December 31, 2019, the\r\nTransition Period ended December 31, 2018 and our fiscal years ended June 30,\r\n2018 and 2017 (which are referred to as \"fiscal 2018,\" and \"fiscal 2017\", as if\r\nwe had not changed our fiscal year to a calendar year). For comparison purposes,\r\nwe have also included unaudited data for the year ended December 31, 2018.\r\n\r\nOverview\r\n\r\nImmunomedics is a clinical-stage biopharmaceutical company developing monoclonal\r\nantibody-based products for the targeted treatment of cancer.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f27%2f0000722830-20-000003.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Loretta M. Itri", "title": "Chief Medical Officer"}, {"name": "Usama Malik", "title": "Chief Financial & Business Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}